In breast cancer, the estrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2), which are predictive of the response to endocrine- and HER2-targeted therapy, respectively, are the most important treatment predictive markers. This evidence concerns the gene ERBB2 and breast carcinoma.